Thermo Fisher Scientific, the global leader in science and innovation, is proud to announce a new development in its Bourgoin, France site – it is now able to offer customers the full range of services for their oral solid dose therapies, from early development to commercial manufacturing. This new addition to the site is a testament to the company’s commitment to helping customers get their medicines to patients faster.
Thermo Fisher is proud to announce the expansion of its global oral solid dose development capabilities with the opening of a new facility in France. This expansion provides the opportunity to forge partnerships with customers and support the development and commercial production of lifesaving drugs for patients. In the last decade, Thermo Fisher has led the field of oral solid dose development, with 126 new drug approvals supported.
In 2021, the French government announced their France Relance economic stimulus plan, which included a grant to kickstart the development of an early development hub. Construction began in the first quarter of 2022, and the hub was ready to open its doors to the public in June of that same year. With this exciting new project, the French government is helping to create a more innovative and prosperous future for the country.
At our early development hub, we have a state-of-the-art 430-square-meter (4,600 square feet) research and development facility for pre-clinical, non-GMP operations, as well as expanded GMP facilities. This facility is designed to provide the best resources for our research and development teams to ensure the highest quality products.
At Thermo Fisher’s center of excellence in Bourgoin, Europe, we offer an extensive range of end-to-end drug product development and high potent substance handling services. From conventional oral solid dose manufacturing equipment to specialized compaction and compression-contained simulation and Accelerated Stability Assessment Program (ASAP) simulation, we are dedicated to providing the best pharmaceutical solutions available.
Bourgoin’s ambitious expansion is an investment in small molecule solutions, including oral solid dose development and manufacturing services. This investment reaches across multiple locations, including Bend, Ore., U.S.; Greenville, N.C., U.S.; Cincinnati, OH, U.S.; Manatí, Puerto Rico; Toronto, Canada; Whitby, Canada; and Milton Park, U.K. With this far-reaching investment, Bourgoin is primed to significantly advance its small molecule solutions.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is on a mission to make the world healthier, cleaner, and safer. With annual revenue over $40 billion, we are the world leader in serving science and are dedicated to supporting our customers in accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics, or developing and manufacturing life-changing therapies.
Our global team combines innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD to provide unmatched products and services.